There are more devices on the way as well such as H-Pal for blood pressure. Full information at the link below. BD
FDA CLEARED – D-PAL is a revolutionary new way for people with diabetes to transfer their daily glucose readings, in near real-time, to a central server for storage and review by their healthcare provider(s). 
D-PAL currently combines with the Polymap Polytel® device that connects to the LifeScan® OneTouch® Ultra®, and sends the data via Bluetooth® (wireless) to the patient’s cell phone (acting as a “Hub”) and transmits the information to a central server. D-PAL is the first of a series of medical devices that integrates with the MedApps System and enables patients with chronic diseases to lead more active lifestyles.
There is an entire category of wireless diabetes devices launching this year.
ReplyDeleteWhat's more important however is the clinical trial data from actual patient use of these cool devices if the manufacturers ever hope for adoption by the medical community.
Much of the 1.1 point drop in A1c experienced by 84% of the patients in the healthcordia trial can be attributed to the simplicity of the device, relevance of the system interactions and the comprehensive nature of the program delivery itself.
We'll have to see how the MedApps kit fares in patient usability studies before we can extend prior research outcomes to other programs that use other more complex devices.
Our understanding is that the MedApps Bluetooth solution involves a regular glucose meter, a third party counter-top device which the patient uses to connect a cable to the meter, the counter-top device in turn communicates via Bluetooth (short-range wireless) to the patient's Bluetooth enabled cell phone, the cell phone in turn receives the data from the counter-top device and in turn transmits the data via the patient's cell phone add-on data plan to a remote system with Internet connectivity where the data is stored, viewed, etc...
Fortunately, healthcordia, llc announced impressive clinical trial results at this year's ADA Scientific Sessions with hard data from actual type 2 adults using Diabetech's GlucoMON® wireless glucose meter, a sophisticated GlucoDYNAMIX™ rules engine, and patient-centric social networks.
The key to outcomes is simplicity, relevance and ultimately its ability to effect behavioral changes. MedApps and the other vendors will have to go through similar usability studies and healthcordia is best positioned to evaluate comparative analysis given its incumbent position managing patients with this sort of wireless diabetes technology.
Ideally, the device community will pay attention to outcomes and patients will ultimately win by having a large portfolio of field-tested and easy to use devices that are capable of supporting patient programs.
Thank you for the information as you can see we are always interested in new medical technology and will watch for any upcoming news releases and events. BD
ReplyDelete